Tag:
Avila Therapeutics
Latest Headlines
Latest Headlines
Three new rules for biopharma collaborations
Last week Ryan McBride moderated a panel called "The New Rules of Partnerships and Collaborations" at the Convergence East conference on Cape Cod, and the experience yielded a chance to probe some of the biopharma industry's top dealmakers about their preferences and prejudices going into talks with other companies.
UPDATED: Celgene snaps up Avila Therapeutics in $925M buyout
In less than five years Avila Therapeutics nailed down a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of
Avila pockets payment in $209M lung cancer drug deal
Avila Therapeutics ( a 2010 Fierce 15 company ) has banked $4 million from partner Clovis Oncology ( $CLVS ). The payment was made as part of Avila's $209 million alliance with Clovis ( a 2009 Fierce 15
Sanofi, Avila ink $800M oncology drug development pact
The dealmaking machine that is Sanofi-Aventis ( $SNY ) is at it again, signing an oncology drug pact worth $40 million up front and up to $154 million in milestone payments per program. Overall, the
Clovis teams up with Avila on $209M lung cancer deal
Avila Therapeutics won an admirer and a collaborator when it inked a $209 million deal to partner up on one of its covalent drug programs with Clovis Oncology, a start-up backed with some serious
Avila teams with Leukemia & Lymphoma Society on early-stage cancer trial
The Leukemia & Lymphoma Society knows how to be patient. Over the last 50 years it's backed hundreds of basic academic research projects on blood cancers, many of which required 15 or 20 or 25
Avila raises $30M, inks deal with Novartis Option Fund
Waltham, MA-based Avila Therapeutics unveiled two major announcements today. First, the developer has closed a $30 million Series B round of funding--enough money to move the company's lead drug into
